ReviewMicroorganisms2022
Modulating Microbiota as a New Strategy for Breast Cancer Prevention and Treatment.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 50 citations in OpenAlex.
- The Human Breast Microbiome: From Homeostasis to Malignancy, Mechanistic Insights and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- The Role of Lactobacillus Strain Probiotics in Breast Cancer: Strain-Specific Mechanisms and Therapeutic Potential Beyond Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Combined Effects of Withaferin A and Sodium Butyrate on NF-κB Signaling and Epigenetic Regulation in Breast Cancer Cells.Nutrients · 2026Article
- Targeting microbiome-driven epigenetic modifications: a new frontier in breast cancer treatment.Clinical epigenetics · 2026Review
- Dysbiosis-Mediated Regulation of Stem Cells the First Hit for Cancer Generation.International journal of molecular sciences · 2026Review
- Effect of oral probiotics on postoperative nutrition level of patients with liver cancer.Open medicine (Warsaw, Poland) · 2026Article
- Exploring the Gut Microbiota as a Promising Target for Breast Cancer Treatment.Current molecular medicine · 2026Review
- Mammary Gland Microbiota in Benign Breast Diseases.International journal of molecular sciences · 2025Review
- Long-Term Breastfeeding: Protective Effects Against Triple-Negative Breast Cancer and the Role of the Breast Microbiota.Pathogens (Basel, Switzerland) · 2025Review
- Influence of Cooking Methods on Flavor Parameters and Sensory Quality of Tibetan Sheep Meat Examined Using an Electronic Nose, an Electronic Tongue, GC-IMS, and GC-MS.Foods (Basel, Switzerland) · 2025Article
- Article
- Molecular Mechanisms in the Carcinogenesis of Oral Squamous Cell Carcinoma: A Literature Review.Biomolecules · 2025Review
- Therapeutic potential of microbiome modulation in reproductive cancers.Medical oncology (Northwood, London, England) · 2025Review
- Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer.Scientific reports · 2025Article
- The microbial landscape of tumors: a deep dive into intratumoral microbiota.Frontiers in microbiology · 2025Review
- The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer.Frontiers in microbiology · 2025Review
- Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy.International journal of molecular sciences · 2024Review
- Nutrition Intervention and Microbiome Modulation in the Management of Breast Cancer.Nutrients · 2024Review
- Epigenetics, Microbiota, and Breast Cancer: A Systematic Review.Life (Basel, Switzerland) · 2024Review
- A novel combinatorial approach using sulforaphane- and withaferin A-rich extracts for prevention of estrogen receptor-negative breast cancer through epigenetic and gut microbial mechanisms.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Breast cancer (BC) is the most common cancer in women in the United States. There has been an increasing incidence and decreasing mortality rate of BC cases over the past several decades. Many risk factors are associated with BC, such as diet, aging, personal and family history, obesity, and some environmental factors. Recent studies have shown that healthy individuals and BC patients have different microbiota composition, indicating that microbiome is a new risk factor for BC. Gut and breast microbiota alterations are associated with BC prognosis. This review will evaluate altered microbiota populations in gut, breast tissue, and milk of BC patients, as well as mechanisms of interactions between microbiota modulation and BC. Probiotics and prebiotics are commercially available dietary supplements to alleviate side-effects of cancer therapies. They also shape the population of human gut microbiome. This review evaluates novel means of modulating microbiota by nutritional treatment with probiotics and prebiotics as emerging and promising strategies for prevention and treatment of BC. The mechanistic role of probiotic and prebiotics partially depend on alterations in estrogen metabolism, systematic immune regulation, and epigenetics regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.